Rinofluimucil is advised against in the following cases:
- Hypersensitivity to the active ingredient or any one of the excipients
- Narrow-angle glaucoma
- Hyperthyroidism
- During and in the two weeks subsequent to therapy with inhibitors of monoamine oxidase (IMAO).
- Children younger than 12 years of age
- Pheochromocytoma
- During the use of other sympathomimetic drugs, including nasal decongestants.
- Hypophysectomy or surgery with exposure of the dura mater.
The data relating to a limited number of women in pregnancy exposed to N-acetylcisteine have not indicated any adverse effect on the pregnancy itself or the health o foetus/new-born. There are moreover none in women in pregnancy exposed to tuaminoheptane or studies on animals with tuaminoheptane. In addition, there is no information available in respect of excretion of N-acetylcisteine and tuaminoheptane in mother’s milk; therefore Rinofluimucil is not recommended in pregnancy or during breastfeeding and should be administered with caution at paediatric age.
In patients with cardiovascular illnesses, and especially the with hypertension, the use of nasal decongestants must be put to the judgment from time to time of the doctor.
Administer with caution in parties affected by occlusive vascular disease, asthma, diabetes and in therapy with beta-blocker medication.
Use the product with caution for the risk of urinary retention in the elderly and in bearers of prostatic hypertrophy.
The use, especially if prolonged, of topic products may give rise to phenomena of sensitising; in this case it is necessary to interrupt treatment and, as the case may be, institute suitable therapy.
In the absence of a complete therapeutic response within a few days, consult a doctor; in any event, treatment must not be protracted for more than a week.
The action of the compound may be integrated, at the discretion of a doctor, with fitting antibacterial cover.
Tuaminoheptane sulphate may show positive to anti-doping.
Important: The preserving agent benzalkonium chloride may cause cutaneous reactions or bronchospasm.